Group 1: Amphastar Pharmaceuticals Inc. - Amphastar Pharmaceuticals Inc. plans to expand its pharmaceutical manufacturing operations in Rancho Cucamonga, California [1] - The expansion includes demolition of a 140,000-sq-ft building and construction of a new 279,507-sq-ft building with cleanrooms [1] - The project will quadruple the plant's capacity to produce injectables, inhalation, and intranasal pharmaceutical products [1] - Construction is expected to begin in 2026, with architectural design services provided by EwingCole [1] Group 2: General Matter Inc. - General Matter Inc. is planning to establish a $1.5-billion uranium enrichment plant in Paducah, Kentucky [2] - The facility will process at least 7,600 cylinders of uranium hexafluoride into low-enriched uranium for nuclear fuel [2] - Construction is expected to begin in 2026, involving renovation and installation of various equipment [2] Group 3: Missouri River Energy Services - Missouri River Energy Services plans to construct a natural gas-fired power plant on a 71-acre site in Toronto, South Dakota [3] - The project includes the construction of a natural gas pipeline and installation of four combustion turbines and generator sets [3] - Bid documents for general construction services are expected to be issued in the third or fourth quarter of 2026 [3]

Financial Data and Key Metrics Changes - The company reported a transition in the distribution of Vaximi, which is now fully under Amphastar's control, leading to double-digit growth in scripts year-to-date [5][6] - The guidance for unit growth this year is high single digits, an improvement from low single-digit growth last year [9][7] - A small price increase in the United States is also contributing to revenue growth [9] Business Line Data and Key Metrics Changes - Vaximi's growth has been strong, with a 16% increase in scripts in July, indicating robust performance [6] - Primatene Mist experienced a 10% year-over-year growth, supported by direct-to-consumer efforts and physician sampling [15][17] - Iron sucrose is expected to enhance the company's margin profile despite increased competition [72] Market Data and Key Metrics Changes - The market for glucagon is shrinking due to competition, but the company maintains a high margin on this product [36][39] - The company anticipates a stable market share for its epinephrine products despite new entrants, due to its reliability as a supplier [42] Company Strategy and Development Direction - Amphastar is focusing on increasing market penetration for glucagon among insulin users, aiming to grow from 12% compliance [10] - The company is diversifying its pipeline, targeting 50% proprietary products by 2026, and has recently licensed preclinical assets in oncology and ophthalmology [67][64] - The company is optimistic about future product approvals, including teriparatide and AMP007, which are expected to contribute positively to margins [33][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving peak sales guidance of $250 million to $275 million for glucagon products [11] - The company is managing tariff impacts on expenses, with an expected cost of $500,000 per quarter due to tariffs on imports [78][80] - Management highlighted the importance of iron sucrose and teriparatide in improving profitability moving forward [81][72] Other Important Information - The company has received FDA recognition as a top supplier for shortage products, enhancing its relationship with the agency [43] - Amphastar is working on a new formulation for Primatene Mist to address environmental concerns, which may further strengthen its market position [20] Q&A Session Summary Question: How has the transition of Vaximi impacted growth? - The transition has led to strong performance, with double-digit growth in scripts year-to-date [5][6] Question: What are the growth drivers beyond 2025? - The focus is on increasing compliance among insulin users for glucagon, with a target of 12% market penetration [10] Question: How does the company view competition in the glucagon market? - The company acknowledges competition but believes its product's ease of use gives it an advantage [13] Question: What is the outlook for Primatene Mist post-patent expiry? - The company believes brand recognition will sustain its market position despite potential competition [18][19] Question: How is the company managing pricing pressures? - The company is implementing cost control measures and focusing on higher-margin products to mitigate pricing pressures [73][72] Question: What is the status of the AMP007 inhalation product? - The product is in the second cycle review, with expectations of being a first generic if approved [48][50]

Company Strategy & Growth Model - Amphastar operates with a "Three-H Focus" on High Quality, High Efficiency, and High Technology to drive pipeline development and achieve high net income margins[8, 15, 17] - The company employs a dual-strategy growth model, combining organic pipeline development with strategic acquisitions[8, 13, 14] - Amphastar is transitioning towards proprietary and biosimilar drugs, projecting a shift from 63% generic, 16% biosimilar, and 21% proprietary in 2021 to 15% generic, 35% biosimilar, and 50% proprietary in 2026[19, 20] Financial Performance - Amphastar's revenue has grown steadily, reaching $732 million in 2024[15, 54] - Adjusted net income margin has increased significantly from 3.5% in 2018 to 27.4% in 2024[15] - The company has invested approximately $351 million in self-funded R&D over the recent 5 years[26] Pipeline Development - Amphastar has a diverse pipeline of ANDAs and BLAs with technical barriers, including 6 generic candidates and 1 biosimilar candidate[29] - The company is developing an interchangeable insulin pipeline, covering the full spectrum of insulin from rapid to long-acting[31, 32] - Amphastar in-licensed 3 new peptide assets (AMP-105, AMP-107, AMP-109) targeting oncology and ophthalmology with a market potential of >$50 billion and >$10 billion respectively[34, 44] Key Products - BAQSIMI® sales are projected to reach a peak of $250 million to $275 million, with an estimated incremental adjusted EPS of $2.00 to $2.50 at peak[61, 66] - BAQSIMI® worldwide annual sales reached $166 million in 2024[65] - Primatene MIST® sales surpassed $100 million in 2024[69]

Core Viewpoint - The FDA has approved Amphastar Pharmaceuticals' Iron Sucrose Injection, which is expected to generate significant sales in the treatment of iron deficiency anemia in patients with chronic kidney disease [1][5]. Group 1: FDA Approval and Market Potential - Amphastar Pharmaceuticals received FDA approval for its Iron Sucrose Injection in various dosages, which is indicated for treating iron deficiency anemia in chronic kidney disease patients [1]. - The U.S. sales for the branded competitor, Venofer, were approximately $513 million for the 12 months ending June 30, 2025, indicating a substantial market opportunity for Amphastar [3]. - Analyst estimates suggest that Amphastar's product could capture about two-thirds of the Venofer market, potentially leading to sales of $80 million to $100 million [5]. Group 2: Financial Performance and Analyst Ratings - Amphastar reported adjusted earnings of 85 cents, surpassing the consensus estimate of 76 cents, while sales fell 4% year-over-year to $174.41 million, slightly above the consensus of $174.25 million [7]. - Analyst Serge Belanger upgraded Amphastar to a Buy rating from Hold, with a price forecast of $36, citing attractive valuation and growth potential for 2025 and 2026 [6]. Group 3: Strategic Partnerships and Future Developments - Amphastar announced an exclusive license agreement with Nanjing Anji Biotechnology to develop and commercialize three proprietary peptides, with potential total payments to Anji reaching up to $453 million [8][9]. - The agreement includes an upfront payment of $5.25 million and additional milestone payments, indicating a strategic move to expand its product portfolio [9].

Core Insights - Amphastar Pharmaceuticals reported revenue of $174.41 million for the quarter ended June 2025, a decrease of 4.4% year-over-year, with EPS at $0.85 compared to $0.94 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $169.84 million, resulting in a surprise of +2.69%, while the EPS surprised by +19.72% against the consensus estimate of $0.71 [1] Revenue Breakdown - Primatene MIST generated net revenues of $22.88 million, slightly below the average estimate of $25.95 million, reflecting a year-over-year change of +0.1% [4] - Glucagon reported net revenues of $20.6 million, significantly lower than the average estimate of $28.32 million, marking a year-over-year decline of -24.7% [4] - Lidocaine achieved net revenues of $15 million, surpassing the average estimate of $13.14 million, with a year-over-year increase of +17.2% [4] - Epinephrine's net revenues were $16.18 million, falling short of the average estimate of $17.77 million, indicating a year-over-year decrease of -42.1% [4] Stock Performance - Amphastar's shares have returned -7.2% over the past month, contrasting with the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Viewpoint - Amphastar Pharmaceuticals reported quarterly earnings of $0.85 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, but down from $0.94 per share a year ago, indicating an earnings surprise of +19.72% [1][2] Financial Performance - The company posted revenues of $174.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.69%, but down from $182.39 million year-over-year [2] - Over the last four quarters, Amphastar has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Stock Performance - Amphastar shares have declined approximately 43.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.83 for the coming quarter and $3.17 for the current fiscal year [7] - The Zacks Rank for Amphastar is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Amphastar belongs, is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Financial Data and Key Metrics Changes - For Q2 2025, the company reported net revenues of $174.4 million, a decrease of 4% year-over-year, with GAAP net income of $31 million or 64¢ per diluted share, down from $37.9 million or 73¢ per share in the previous year [4][18] - Adjusted net income was $40.9 million or 85¢ per diluted share, compared to $48.7 million or 94¢ per diluted share in the same quarter last year [18] - Gross margins declined to 49.6% from 52.2% year-over-year, primarily due to increased competition and the transition of sales from Lilly [15] Business Line Data and Key Metrics Changes - Vaximi sales increased by 21% year-over-year, reaching $40.5 million, driven by successful global commercialization and higher average selling prices [5][13] - Primatene Mist sales remained steady at $22.9 million, with year-to-date sales growing by 10% [14] - Glucagon injection sales decreased by 25% to $20.6 million, and epinephrine sales dropped by 42% to $16.2 million due to increased competition [14] - Sales of lidocaine increased by 17% to $15 million, attributed to higher unit volumes amid supply shortages [14] Market Data and Key Metrics Changes - The company noted a shift in the market towards ready-to-use glucagon products, impacting traditional glucagon sales [36] - The competitive landscape for epinephrine prefilled syringes has intensified, contributing to both pricing and unit sales declines [32] Company Strategy and Development Direction - The company is focusing on expanding its U.S. manufacturing capacity to mitigate international supply chain risks and support its R&D pipeline [6][10] - There is a strategic shift towards proprietary product development, with an emphasis on branded products and operational excellence [11][12] - The company aims to maintain fiscal discipline while investing in high-impact opportunities, with R&D expenses rising by 14% year-over-year [11][17] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the approval of product candidate AMP-002, citing productive discussions with the FDA [7][23] - The company anticipates flat sales year-over-year, with potential contributions from new product approvals [20][21] - Management expects increased price competition in the glucagon market, which may lead to margin contraction unless offset by new product launches [31] Other Important Information - The company has initiated a $50 million stock buyback program following the completion of a previous authorization [18] - The expansion of manufacturing capacity is designed to support the pipeline and proprietary products, reflecting a long-term growth strategy [38] Q&A Session Summary Question: Expectations for top-line growth and Vaximi's performance - Management maintains guidance for flat sales year-over-year, with Vaximi expected to show high single-digit unit growth and a 3% price increase in the U.S. [20][21] Question: Confidence in AMP-002 approval - Management remains optimistic about AMP-002's approval, citing ongoing engagement with FDA officials [23] Question: Market opportunity for AMP-018 and competitive landscape - Management views the GLP-1 market as crowded and expects AMP-018 to be a relatively small contributor to sales [27] Question: Margin trajectory and epinephrine competition - Expected margin trajectory is influenced by new product approvals, but increased price competition in glucagon is anticipated to contract margins [31] Question: Future revenue expectations for glucagon and manufacturing expansion - Management expects glucagon revenues to decline due to competition and market shifts, while the manufacturing expansion is aimed at supporting the product pipeline [36][38] Question: Revenue guidance and product launches - Revenue guidance includes expectations for two product launches, with potential for flat sales depending on competition and Vaximi's performance [41][43]

Company Strategy & Business Model - Amphastar focuses on a "Three-H" strategy: High Quality, High Efficiency, and High Technology, aiming for high net income margins[8, 15, 17] - The company employs a dual-strategy growth model, combining organic pipeline development with strategic acquisitions[8, 13, 14] - Amphastar operates with a fully integrated business model, encompassing R&D, manufacturing, and distribution[8, 9, 10] Financial Performance & Pipeline Evolution - Amphastar's revenue increased from $295 million in 2018 to $732 million in 2024[15] - Adjusted net income margin grew from 3.5% in 2018 to 27.4% in 2024[15] - The company is shifting its pipeline focus from generic drugs (63% in 2021) towards biosimilars (35%) and proprietary products (50%) by 2026[20] Key Products & Milestones - BAQSIMI sales are projected to reach a peak of $250 million to $275 million[47] - Primatene MIST sales surpassed $100 million in 2024[55] - The company has invested approximately $351 million in R&D over the past 5 years[26]

Part I. FINANCIAL INFORMATION [Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed consolidated financial statements for June 30, 2025, present the company's financial position, performance, and cash flows [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets increased to **$1.615 billion**, driven by cash and inventories, while total equity reached **$757.5 million** Condensed Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $580,830 | $534,071 | | Cash and cash equivalents | $187,689 | $151,609 | | Inventories, net | $191,731 | $153,741 | | **Total Assets** | **$1,615,333** | **$1,577,470** | | **Total Current Liabilities** | $176,407 | $173,759 | | Long-term debt, net | $607,727 | $601,630 | | **Total Liabilities** | **$857,851** | **$845,172** | | **Total Stockholders' Equity** | **$757,482** | **$732,298** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net revenues for Q2 2025 decreased to **$174.4 million**, with net income of **$31.0 million**, reflecting a year-over-year decline Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 | | :--- | :--- | :--- | :--- | :--- | | Total net revenues | $174,414 | $182,394 | $344,942 | $354,230 | | Gross profit | $86,490 | $95,166 | $171,741 | $185,266 | | Income from operations | $42,184 | $55,217 | $79,477 | $103,227 | | **Net income** | **$31,030** | **$37,949** | **$56,315** | **$81,126** | | Diluted EPS | $0.64 | $0.73 | $1.15 | $1.54 | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash from operations decreased to **$70.7 million**, primarily due to increased inventories Cash Flow Summary (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $70,669 | $124,400 | | Net cash provided by (used in) investing activities | $9,856 | $(54,666) | | Net cash used in financing activities | $(44,705) | $(24,295) | | **Net increase in cash** | **$36,080** | **$45,323** | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed information on accounting policies, revenue recognition, segment reporting, and debt - The company operates as a single reportable segment: pharmaceutical products[68](index=68&type=chunk) Net Revenues by Key Product (in thousands) | Product | YTD 2025 | YTD 2024 | Change % | | :--- | :--- | :--- | :--- | | BAQSIMI® | $85,042 | $44,697 | +90.3% | | Primatene MIST® | $51,931 | $47,022 | +10.4% | | Glucagon | $41,445 | $55,908 | -25.9% | | Epinephrine | $34,767 | $54,051 | -35.7% | | Lidocaine | $28,643 | $25,573 | +12.0% | - Three major customers, McKesson, Cencora, and Cardinal Health, accounted for **29%**, **27%**, and **15%** of total accounts receivable, respectively, as of June 30, 2025[71](index=71&type=chunk) - The company has **$345 million** in 2.0% Convertible Senior Notes due 2029 and a **$250 million** term loan due 2028[89](index=89&type=chunk)[90](index=90&type=chunk) - During the six months ended June 30, 2025, the company repurchased **1,935,696 shares** of its common stock for a total of **$50.0 million** under its share buyback program[112](index=112&type=chunk) [Management's Discussion and Analysis (MD&A)](index=46&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the **4%** decrease in Q2 2025 net revenues, driven by lower legacy product sales despite **BAQSIMI®** growth, impacting gross margin [Results of Operations](index=48&type=section&id=Results%20of%20Operations) Net product revenues for Q2 2025 decreased by **3%**, as **BAQSIMI®** growth was offset by declines in legacy products, leading to a gross margin decline to **50%** Q2 2025 vs Q2 2024 Product Revenue Changes (in thousands) | Product | Q2 2025 Revenue | Q2 2024 Revenue | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | BAQSIMI® | $46,687 | $30,854 | $15,833 | 51% | | Epinephrine | $16,180 | $27,941 | $(11,761) | (42)% | | Glucagon | $20,602 | $27,373 | $(6,771) | (25)% | - The increase in **BAQSIMI®** sales was driven by growth in unit volumes as the company assumed full global distribution responsibilities at the beginning of 2025[159](index=159&type=chunk) - The decrease in epinephrine and glucagon sales was attributed to increased competition and, for glucagon, a market shift towards ready-to-use products like **BAQSIMI®**[159](index=159&type=chunk) - R&D expenses increased by **14%** in Q2 2025 to **$20.1 million**, primarily due to higher material and supply expenses for inhalation pipeline products and increased depreciation[167](index=167&type=chunk)[169](index=169&type=chunk) [Liquidity and Capital Resources](index=58&type=section&id=Liquidity%20and%20Capital%20Resources) The company had **$187.7 million** in cash and **$404.4 million** in working capital as of June 30, 2025, with operating cash flow decreasing to **$70.7 million** - Working capital increased by **$44.1 million** to **$404.4 million** at June 30, 2025, from **$360.3 million** at December 31, 2024[194](index=194&type=chunk) - Net cash provided by operating activities decreased to **$70.7 million** for the first half of 2025 from **$124.4 million** in 2024, largely due to an increase in inventories as the company took over the **BAQSIMI®** supply chain[196](index=196&type=chunk)[197](index=197&type=chunk) - Net cash used in financing activities was **$44.7 million**, primarily driven by **$50.2 million** in treasury stock purchases[203](index=203&type=chunk) [Quantitative and Qualitative Disclosure about Market Risk](index=65&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosure%20about%20Market%20Risk) The company is exposed to market risks including investment, interest rate, and foreign currency exchange risks, with no material changes from its 2024 10-K - The company identifies its primary market risks as changes in the value of its investments, interest rate fluctuations, and foreign currency exchange rate changes[212](index=212&type=chunk) [Controls and Procedures](index=65&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal controls - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by the report[213](index=213&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[214](index=214&type=chunk) Part II. OTHER INFORMATION [Legal Proceedings](index=66&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal proceedings, including two employment litigations in California, and intends to vigorously defend itself - The company is facing two employment litigations from former employees with individual and class action claims for alleged violations of the California Labor Code[144](index=144&type=chunk)[145](index=145&type=chunk) - The company has recorded an estimated liability of **$11.0 million** for a property and casualty claim, which is fully covered by its insurance policies[146](index=146&type=chunk) [Risk Factors](index=66&type=section&id=Item%201A.%20Risk%20Factors) The company highlights several key risks, including manufacturing disruptions, trade tariffs, cybersecurity threats, and executive stock pledges - A significant portion of manufacturing takes place in China, exposing the company to risks from political unrest, tariffs, health epidemics, and changes in trade laws which could adversely affect business[218](index=218&type=chunk)[219](index=219&type=chunk) - The company faces risks from enhanced trade tariffs and restrictions, with significant uncertainty about the future trade relationship between the United States and China[222](index=222&type=chunk) - The company and its third-party providers have experienced and may continue to experience cyber-attacks, including past security breaches at its Chinese subsidiary and illegal obtaining of employee personal information[227](index=227&type=chunk) - Executives Jack Y. Zhang and Mary Z. Luo have pledged a total of **3,601,156 shares** of common stock as collateral for loans, where a forced sale could cause the stock price to decline[235](index=235&type=chunk)[236](index=236&type=chunk) [Issuer Purchases of Equity Securities](index=74&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q2 2025, the company repurchased **1,541,860 shares** at an average price of **$25.30**, with an additional **$50.0 million** authorized for buybacks Share Repurchases in Q2 2025 | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | April 2025 | 554,282 | $25.24 | | May 2025 | 528,481 | $24.58 | | June 2025 | 459,097 | $26.12 | - On August 5, 2025, the Board of Directors authorized a **$50.0 million** increase to the share buyback program, which does not have an expiration date[242](index=242&type=chunk) [Other Information](index=74&type=section&id=Item%205.%20Other%20Information) No officers or directors adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the last fiscal quarter - No officers or directors adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading plan during the second quarter of 2025[245](index=245&type=chunk) [Exhibits](index=76&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including amendments to bylaws, manufacturing agreements, and CEO/CFO certifications

Financial Performance Summary [Q2 2025 Highlights](index=1&type=section&id=Second%20Quarter%202025%20Highlights) Q2 2025 saw a 4% revenue decrease, driven by BAQSIMI® growth, alongside a major manufacturing capacity expansion Financial Metric (in thousands) | Financial Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | Six Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | **Net Revenues** | $174,414 | $182,394 | $344,942 | $354,230 | | **GAAP Net Income** | $31,030 | $37,949 | $56,315 | $81,126 | | **Adjusted non-GAAP Net Income** | $40,893 | $48,688 | $77,764 | $103,984 | | **GAAP Diluted EPS** | $0.64 | $0.73 | $1.15 | $1.54 | | **Adjusted non-GAAP Diluted EPS** | $0.85 | $0.94 | $1.59 | $1.98 | - BAQSIMI® has become a key revenue driver in 2025, with its total sales growing **21%** compared to the same period last year (including prior sales by Lilly)[3](index=3&type=chunk) - The company announced the largest domestic infrastructure investment in its history, a multi-year plan to quadruple manufacturing capacity at its Rancho Cucamonga headquarters to mitigate risks from international supply chains[3](index=3&type=chunk) Detailed Financial Analysis [Revenue Analysis](index=1&type=section&id=Revenue%20Analysis) Q2 2025 net revenues decreased 4%, with BAQSIMI® growth offset by declines in Epinephrine and Glucagon due to competition Product Revenue (in thousands) | Product | Q2 2025 Revenue (in thousands) | Q2 2024 Revenue (in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | BAQSIMI® | $46,687 | $30,854 | 51% | | Primatene MIST® | $22,880 | $22,856 | 0% | | Glucagon | $20,602 | $27,373 | -25% | | Epinephrine | $16,180 | $27,941 | -42% | | Lidocaine | $14,999 | $12,800 | 17% | | Other products | $53,066 | $57,564 | -8% | | **Total product revenues, net** | **$174,414** | **$179,388** | **-3%** | | Other revenues | $0 | $3,006 | -100% | | **Total net revenues** | **$174,414** | **$182,394** | **-4%** | - **BAQSIMI®:** Sales increased due to higher unit volume[9](index=9&type=chunk) - **Epinephrine:** Sales decreased due to lower unit volumes as competitors returned to historical distribution levels and competition increased for the multi-dose vial product[9](index=9&type=chunk) - **Glucagon:** Sales decreased due to lower average selling price (**$4.7 million** impact) and lower unit volumes (**$2.1 million** impact) from competition[9](index=9&type=chunk) - **Lidocaine:** Sales increased due to higher demand caused by shortages from other suppliers[9](index=9&type=chunk) [Profitability and Operating Expenses](index=3&type=section&id=Profitability%20and%20Operating%20Expenses) Q2 2025 gross profit fell 9% to **$86.5 million**, with margin contracting to 49.6%, while operating expenses rose 11% Gross Profit (in thousands) | Metric | Q2 2025 (in thousands) | Q2 2024 (in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Net revenues | $174,414 | $182,394 | -4% | | Cost of revenues | $87,924 | $87,228 | 1% | | **Gross profit** | **$86,490** | **$95,166** | **-9%** | | **Gross margin** | **49.6%** | **52.2%** | -2.6 p.p. | Operating Expense (in thousands) | Operating Expense | Q2 2025 (in thousands) | Q2 2024 (in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Selling, distribution, and marketing | $10,235 | $9,012 | 14% | | General and administrative | $13,991 | $13,285 | 5% | | Research and development | $20,080 | $17,652 | 14% | - The increase in operating expenses was primarily driven by: - **Selling, distribution, and marketing:** Expanded efforts for BAQSIMI®, including a co-promotion contract with MannKind, and sales efforts for Primatene MIST®[10](index=10&type=chunk) - **Research and development:** Increased material and supply expenses for the inhalation pipeline, higher depreciation, and increased clinical trial expenses[10](index=10&type=chunk) [Non-Operating Items and Cash Flow](index=4&type=section&id=Non-Operating%20Items%20and%20Cash%20Flow) Net non-operating expenses decreased to **$2.8 million** in Q2 2025, driven by lower interest expense, with operating cash flow at **$70.7 million** - Cash flow provided by operating activities for the six months ended June 30, 2025, was **$70.7 million**[12](index=12&type=chunk) Non-Operating Item (in thousands) | Non-Operating Item | Q2 2025 (in thousands) | Q2 2024 (in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Interest income | $1,921 | $3,337 | -42% | | Interest expense | $(6,281) | $(8,609) | -27% | | Other income (expenses), net | $1,511 | $298 | 407% | | **Total non-operating expenses, net** | **$(2,849)** | **$(4,974)** | **-43%** | - The decrease in net non-operating expenses was primarily due to lower interest expense from the repayment of a mortgage loan and accretion of interest on the deferred payment for BAQSIMI®, both paid in full in June 2024[18](index=18&type=chunk) Corporate Developments and Outlook [Share Buyback Program](index=4&type=section&id=Share%20Buyback%20Program) The Board authorized a **$50 million** increase to the share buyback program, primarily to offset equity compensation dilution indefinitely - The Board of Directors authorized a **$50 million** increase to the Company's share buyback program on August 5, 2025[13](index=13&type=chunk) - The primary goal of the program is to offset dilution from the Company's equity compensation programs and it is expected to continue for an indefinite period[13](index=13&type=chunk) [R&D Pipeline](index=4&type=section&id=Pipeline%20Information) The R&D pipeline includes four ANDAs and one biosimilar insulin candidate targeting over **$3 billion**, plus other products targeting over **$7 billion** - The company currently has four ANDAs and one biosimilar insulin candidate filed with the FDA, targeting products with a combined market size exceeding **$3 billion**[15](index=15&type=chunk) - There are also three biosimilar products in development targeting a market size over **$6 billion**, and two generic products in development targeting a market over **$1 billion**[15](index=15&type=chunk) Financial Statements [Condensed Consolidated Statement of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statement%20of%20Operations) Q2 2025 total net revenues were **$174.4 million**, gross profit **$86.5 million**, and net income **$31.0 million** (**$0.64** diluted EPS) Statement of Operations (in thousands) | Line Item (in thousands) | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | Total net revenues | $174,414 | $182,394 | | Gross profit | $86,490 | $95,166 | | Income from operations | $42,184 | $55,217 | | Net income | $31,030 | $37,949 | | Diluted EPS | $0.64 | $0.73 | [Condensed Consolidated Balance Sheets](index=9&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were **$1.615 billion**, cash **$187.7 million**, liabilities **$857.9 million**, and equity **$757.5 million**, showing growth Balance Sheet (in thousands) | Balance Sheet Item (in thousands) | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $187,689 | $151,609 | | Total current assets | $580,830 | $534,071 | | **Total assets** | **$1,615,333** | **$1,577,470** | | Total current liabilities | $176,407 | $173,759 | | **Total liabilities** | **$857,851** | **$845,172** | | **Total equity** | **$757,482** | **$732,298** | [Reconciliation of GAAP to Non-GAAP Measures](index=5&type=section&id=Reconciliation%20of%20Non-GAAP%20Measures) The company reconciles GAAP to non-GAAP measures by excluding non-cash expenses, resulting in Q2 2025 non-GAAP net income of **$40.9 million** and diluted EPS of **$0.85** - The company discloses non-GAAP measures, such as Adjusted non-GAAP net income and Adjusted non-GAAP diluted EPS, to provide a better understanding of its ongoing operations by excluding items like amortization expense, share-based compensation, and other one-time events[19](index=19&type=chunk) Reconciliation (in thousands) | Reconciliation (in thousands) | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | | :--- | :--- | :--- | | **GAAP net income** | **$31,030** | **$37,949** | | Intangible asset amortization | $6,269 | $6,193 | | Share-based compensation | $6,382 | $5,780 | | Expenses related to BAQSIMI® acquisition | $0 | $1,825 | | Income tax provision on pre-tax adjustments | $(2,788) | $(3,059) | | **Adjusted non-GAAP net income** | **$40,893** | **$48,688** | Other Information [Conference Call Information](index=4&type=section&id=Conference%20Call%20Information) A conference call to discuss Q2 2025 financial results will be held on August 7, 2025, at 2:00 p.m. Pacific Time, with access via webcast - A conference call to discuss financial results will be held on August 7, 2025, at 2:00 p.m. Pacific Time[16](index=16&type=chunk) - The call can be accessed via toll-free number (877) 407-0989 or on the Investors page of the company's website, www.amphastar.com[16](index=16&type=chunk)[17](index=17&type=chunk)